These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31732691)

  • 1. Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach.
    Langille SE
    PDA J Pharm Sci Technol; 2020; 74(3):359-366. PubMed ID: 31732691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection.
    Melchore JA; Berdovich D
    PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving "Zero" Defects for Visible Particles in Injectables.
    Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R
    PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Particulate matter in injectable drug products.
    Langille SE
    PDA J Pharm Sci Technol; 2013; 67(3):186-200. PubMed ID: 23752747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The need for new control strategies for particulate matter in parenterals.
    Poms J; Sacher S; Nixdorf M; Dekner M; Wallner-Mang S; Janssen I; Khinast JG; Schennach R
    Pharm Dev Technol; 2019 Jul; 24(6):739-750. PubMed ID: 30821571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial.
    Timmons CL; Liu CY; Merkle S
    PDA J Pharm Sci Technol; 2017; 71(5):379-392. PubMed ID: 28512178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Container Closure Integrity Testing-Practical Aspects and Approaches in the Pharmaceutical Industry.
    Brown H; Mahler HC; Mellman J; Nieto A; Wagner D; Schaar M; Mathaes R; Kossinna J; Schmitting F; Dreher S; Roehl H; Hemminger M; Wuchner K
    PDA J Pharm Sci Technol; 2017; 71(2):147-162. PubMed ID: 27789803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP perspectives on particle contamination of injectable products.
    Gallelli JF; Groves MJ
    J Parenter Sci Technol; 1993; 47(6):289-92. PubMed ID: 8120733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particulate Study on NeoProfen, a Neonatal Injectable Product.
    Krishna A; Rice M; Kester T; Waters M; Wilson T
    PDA J Pharm Sci Technol; 2016; 70(1):76-92. PubMed ID: 26889056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations.
    Ayres JD
    PDA J Pharm Sci Technol; 2018; 72(6):626-639. PubMed ID: 30158238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategy for reducing particulate contamination on opening glass ampoules and development of evaluation methods for its application.
    Lee KR; Chae YJ; Cho SE; Chung SJ
    Drug Dev Ind Pharm; 2011 Dec; 37(12):1394-401. PubMed ID: 21702739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The scientific basis for visible particle inspection.
    Knapp JZ
    PDA J Pharm Sci Technol; 1999; 53(6):291-302. PubMed ID: 10754727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Absolute" sterility and "absolute" freedom from particle contamination.
    Knapp JZ
    PDA J Pharm Sci Technol; 1998; 52(4):173-81. PubMed ID: 9752713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interlaboratory comparison about feasibility of insoluble particulate matter test for injections with reduced test volume in light obscuration method.
    Harazono A; Shibata H; Kiyoshi M; Muto T; Fukuda J; Torisu T; Saitoh S; Nishimura H; Uchiyama S; Ishii-Watabe A
    Biologicals; 2019 Jan; 57():46-49. PubMed ID: 30553568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Particulate contamination in parenterals: current issues.
    Groves MJ
    Boll Chim Farm; 1991 Oct; 130(9):347-54. PubMed ID: 1799429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Risk- and Science-Based Approach to the Acceptance Sampling Plan Inspection of Protein Parenteral Products.
    Spasoff A; Bennis A; Atkinson S; Elliott C; Freund E; Narhi L
    J Pharm Sci; 2018 Sep; 107(9):2306-2309. PubMed ID: 29859961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing Patient Safety through the Use of a Pharmaceutical Glass Designed To Prevent Cracked Containers.
    Schaut RA; Hoff KC; Demartino SE; Denson WK; Verkleeren RL
    PDA J Pharm Sci Technol; 2017; 71(6):511-528. PubMed ID: 28928290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.